It has been previously demonstrated that glypican-3 (GPC3) is differentially expressed in hepatocellular carcinomas (HCC), making it a promising target for radiopharmaceutical therapy to treat HCC. At the ongoing meeting of the European Association of Nuclear Medicine in Vienna, researchers from Rayzebio Inc. and Peptidream Inc. presented the preclinical characterization of a novel proprietary peptide binder of GPC3, RAYZ-8009.
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with documented efficacy in non-small-cell lung cancer. However, in most cases, patients develop resistance to this treatment by mechanisms that are not clear in half of the cases. Researchers from Shanghai Pulmonary Hospital presented data on BC-3448, a bispecific antibody targeting EGFR and CD3 aimed to recruit T cells to tumors with high EGFR expression leading to T cell-driven tumor cell killing. The compound presents a stronger binding affinity for EGFR than for CD3 to avoid the development of cytokine release syndrome, which is a safety issue common in CD3-based bispecific antibodies.
Alzheimer’s disease (AD) has a new candidate for its treatment. Nasal anti-CD3 monoclonal antibody (MAb) reduced microglia activation in the brain of mice without its effect being dependent on the β-amyloid (Aβ) deposits characteristic of this neurodegenerative disorder. “We have done many basic studies in the laboratory on microglia. Microglia activation occurs in many neurologic diseases. One of them is multiple sclerosis (MS). And it also occurs in AD,” senior author Howard Weiner told BioWorld.
Insilico Medicine IP Ltd. has synthesized membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Merck Sharp & Dohme Corp. has disclosed adenosine A2A (ADORA2A) and/or A2B (ADORA2B) receptor antagonists reported to be useful for the treatment of cancer.
Researchers at Xuzhou Medical University have evaluated the inhibitory effect of mitochondrial metabolism inhibitor mitolonidamine (Mito-LND) on the growth of glioblastoma (GBM) cells and studied its potential mechanism.
Researchers from Beijing Inno Medicine Co. Ltd. recently reported preclinical data for the novel liposome encapsulated rosuvastatin calcium candidate, YN-001, being developed for the treatment of atherosclerosis.
RSS
